Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms
Presented at the American Society of Hematology annual meeting, demonstrating GenoPredicta’s ability to identify genomic resistance mechanisms from both sample types with clinical-grade sensitivity.
Related Resources
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Highlights:
•EloLenDex is associated with 4-year PFS of 89% in patients with high-risk SMM
•Immune reactivity, post-therapy immune normalization are associated with longer PFS
•Higher abundance of GZMK+ cytotoxic T cells is associated with longer PFS
•Blood-based immune profiling detects immune dysregulation associated with disease
Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance — AACR 2026
Presented at AACR; demonstrates GenoPredicta’s whole-genome sequencing from as few as ~50 circulating tumor cells, with 100% concordance to bone marrow and FISH and detection of subclonal, resistance-associated alterations from blood.
GenoPredicta™ Specimen Collection Instructions
Step-by-step prep, collection, packaging, and shipping instructions for blood or bone marrow samples.
Predicta Newsletter
Enter your email address to subscribe.
Enter Email Address:
Predicta Biosciences
750 Main Street, Lab 413
Cambridge, MA 02139